11/9
10:49 am
crvs
Corvus Pharmaceuticals: Moving Slowly Forward [Seeking Alpha]
Medium
Report
Corvus Pharmaceuticals: Moving Slowly Forward [Seeking Alpha]
11/4
04:13 pm
crvs
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
Low
Report
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
11/4
04:01 pm
crvs
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results
Low
Report
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results
11/3
09:02 am
crvs
Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting & Exposition
Low
Report
Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting & Exposition
10/31
07:30 am
crvs
Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
Medium
Report
Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
10/29
10:07 am
crvs
Corvus Pharmaceuticals (NASDAQ:CRVS) was given a new $13.00 price target on by analysts at Mizuho.
Low
Report
Corvus Pharmaceuticals (NASDAQ:CRVS) was given a new $13.00 price target on by analysts at Mizuho.
10/28
04:01 pm
crvs
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025
Low
Report
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025
10/17
10:00 am
crvs
Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025
Medium
Report
Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025
10/14
07:57 am
crvs
Corvus Pharmaceuticals (NASDAQ:CRVS) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Low
Report
Corvus Pharmaceuticals (NASDAQ:CRVS) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
10/13
07:04 am
crvs
Corvus Pharmaceuticals (NASDAQ:CRVS) was given a new $16.00 price target on by analysts at Barclays PLC. They now have an "overweight" rating on the stock.
Low
Report
Corvus Pharmaceuticals (NASDAQ:CRVS) was given a new $16.00 price target on by analysts at Barclays PLC. They now have an "overweight" rating on the stock.
10/2
04:11 pm
crvs
Corvus Pharmaceuticals Appoints David Moore to Board of Directors [Yahoo! Finance]
Low
Report
Corvus Pharmaceuticals Appoints David Moore to Board of Directors [Yahoo! Finance]
10/2
04:01 pm
crvs
Corvus Pharmaceuticals Appoints David Moore to Board of Directors
Low
Report
Corvus Pharmaceuticals Appoints David Moore to Board of Directors